ClinicalTrials.gg
RecruitingNCT07921069Updated Nov 6, 2026

Sensory Integration Therapy vs Conventional Physical Therapy in Children With Mixed Cerebral Palsy

An interventional study of Sensory Integration Therapy and Conventional Physical Therapy in Cerebral Palsy, sponsored by Riphah International University. Recruiting at 1 site in Pakistan. Open to participants aged 4 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Riphah International University · Not applicable, Interventional, and Treatment

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
4 Years to 10 Years
Sex
All
01

Study summary

The study aims to compare Sensory Integration Therapy (SIT) with Conventional Physical Therapy (CPT) for improving gross motor function in children aged 4-10 years with mixed cerebral palsy. This randomized controlled trial plans to include 50 participants divided into two groups. Group A will receive Sensory Integration Therapy, while Group B will receive Conventional Physical Therapy over a 12-week intervention period. Outcomes will be assessed using the Gross Motor Function Measure (GMFM-88), Short Sensory Profile (SSP), and Parent-Reported Functional Independence \& Daily Activity Performance (PR-FADAP). Data will be analyzed using SPSS version 26, with statistical significance set at p \< 0.05. The study is expected to determine which intervention is more effective in improving gross motor function and sensory processing in children with mixed cerebral palsy.

Read the detailed description

This randomized controlled trial aims to determine the effectiveness of Sensory Integration Therapy (SIT) compared with Conventional Physical Therapy (CPT) in improving gross motor function in children aged 4-10 years with mixed cerebral palsy. A total of 50 participants will be randomly allocated to two groups and receive their respective interventions for 12 weeks. Outcomes will be assessed using the Gross Motor Function Measure (GMFM-88), Short Sensory Profile (SSP), and PR-FADAP questionnaire. Data will be analyzed using SPSS version 26 to compare changes between the two groups.

02

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • Sensory Integration Therapy
  • Conventional Physical Therapy
  • Mixed Cerebral Palsy
  • Gross Motor Function
  • Gross Motor Function Measure (GMFM-88)
  • Short Sensory Profile (SSP)
  • Pediatric Rehabilitation
03

In context

Cerebral Palsy

1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.

This study's planned enrollment of 50 is above the median of 34 across 1,431 interventional studies indexed under Cerebral Palsy.

Browse Cerebral Palsy studies →

Lead sponsor

Riphah International University is the lead sponsor of 2,193 studies on the registry; 650 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

**Inclusion Criteria:**

  1. Children diagnosed with mixed cerebral palsy.
  2. Medically stable children who are able to participate in the intervention sessions.
  3. Parent or legal guardian willing to provide written .

**Exclusion Criteria:**

  1. Children with severe cognitive or visual impairments.
  2. Children with uncontrolled seizures.
  3. Children with orthopedic deformities requiring surgery.
  4. Children who have received botulinum toxin injections within the previous six months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Sensory Integration Therapy (SIT)

    Participants will receive Sensory Integration Therapy for 12 weeks, involving graded vestibular, tactile, and proprioceptive stimulation, balance and coordination activities, visual-motor tasks, multisensory play, and functional activities to improve gross motor function and sensory processing.

    Behavioral: Sensory Integration Therapy

  • Active comparator
    Conventional Physical Therapy

    Participants will receive conventional physical therapy for 12 weeks, including stretching, range-of-motion exercises, muscle strengthening, postural control, static and dynamic balance training, gait training, transitional movements, stair climbing, and functional task practice to improve gross motor function.

    Behavioral: Conventional Physical Therapy

Interventions

  • BehavioralSensory Integration Therapy

    A 12-week sensory-motor intervention involving vestibular, tactile, and proprioceptive stimulation, balance and coordination activities, visual-motor tasks, graded multisensory challenges, and functional activities. The protocol specifies sessions of 60 minutes, with frequency progressing from 3 to 5 sessions per week.

  • BehavioralConventional Physical Therapy

    A 12-week conventional physical therapy program involving stretching, range-of-motion exercises, muscle strengthening, postural alignment, balance training, gait training, transitional movements, stair climbing, endurance activities, and functional task practice. The protocol specifies sessions of 60 minutes, with frequency progressing from 3 to 5 sessions per week.

06

What researchers measure

Primary outcomes

  1. Change in Gross Motor Function Measure-88 (GMFM-88) Score

    Gross motor function will be assessed using the Gross Motor Function Measure-88 (GMFM-88), a standardized tool for evaluating motor function in children with cerebral palsy. Changes in scores will be compared between the Sensory Integration Therapy group and the Conventional Physical Therapy group.

    Time frame: Baseline and immediately after the 12-week intervention.

Secondary outcomes

  1. Change in Short Sensory Profile (SSP) Score

    Sensory processing behaviors will be assessed using the Short Sensory Profile (SSP). Changes in scores from baseline to post-intervention will be compared between the two treatment groups.

    Time frame: Baseline and immediately after the 12-week intervention.

  2. Change in Functional Independence and Daily Activity Performance

    Functional independence and daily activity performance will be assessed using the Parent-Reported Functional Independence \& Daily Activity Performance (PR-FADAP) questionnaire, as specified in the study protocol. Changes in scores will be compared between the two treatment groups.

    Time frame: Baseline and immediately after the 12-week intervention.

07

Study locations

1 of 1 sites recruiting
  • Akhbar kare center Peshawar
    Peshawar, Kpk 25000, Pakistan
    Recruiting
    • · Contact091-5822509
08

References and documents

Publications

  • Bax M, Goldstein M, Rosenbaum P, Leviton A, Paneth N, Dan B, Jacobsson B, Damiano D; Executive Committee for the Definition of Cerebral Palsy. Proposed definition and classification of cerebral palsy, April 2005. Dev Med Child Neurol. 2005 Aug;47(8):571-6. doi: 10.1017/s001216220500112x. PubMed 16108461 ↗
  • Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil. 2006 Feb 28;28(4):183-91. doi: 10.1080/09638280500158422. PubMed 16467053 ↗
  • Khandaker G, Muhit M, Karim T, Smithers-Sheedy H, Novak I, Jones C, Badawi N. Epidemiology of cerebral palsy in Bangladesh: a population-based surveillance study. Dev Med Child Neurol. 2019 May;61(5):601-609. doi: 10.1111/dmcn.14013. Epub 2018 Nov 5. PubMed 30394528 ↗
  • Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B. A report: the definition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007 Feb;109:8-14. PubMed 17370477 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

Of 902 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 6 months is below that.

Counting every sponsor, half of 921 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 6, 2026
StartActual
Oct 21, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07921069
Collaborators
Northwest General Hospital and Research centre
Responsible party
Sponsor
First posted
Nov 6, 2026
Start date
Oct 21, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Salim Khan Dr. Salim Khan, MS
Contact
salim.khan@akbarkare.org
091-5822509
Zobia Naeem, MS'
principal investigator · Riphah International University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion